Alternatively activated macrophages in the pathogenesis of chronic kidney allograft injury

Pediatric Nephrology

Volumn 30, Issue 6, 2015, Pages 1007-1017

  Ikezumi, Yohei ^a   Suzuki, Toshiaki ^a   Yamada, Takeshi ^a   Hasegawa, Hiroya ^a   Kaneko, Utako ^a   Hara, Masanori ^b   Yanagihara, Toshio ^b   Nikolic Paterson, David J ^c   Saitoh, Akihiko ^a  

^a NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^b Yoshida Hospital   (Japan)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Alternatively activated macrophages; CD163; Chronic allograft injury; Fibrosis; IF TA NOS; Urinary CD163

Indexed keywords

BIOLOGICAL MARKER; CD163 ANTIGEN; CD68 ANTIGEN, HUMAN; CELL SURFACE RECEPTOR; DEXAMETHASONE; DIFFERENTIATION ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN;

ADOLESCENT; ADULT; ADVERSE EFFECTS; ALLOGRAFT; ATROPHY; BIOPSY; CELL CULTURE; CHILD; DRUG EFFECTS; FEMALE; FIBROSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KIDNEY; KIDNEY TRANSPLANTATION; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; METABOLISM; PATHOLOGY; PHENOTYPE; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ALLOGRAFTS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ATROPHY; BIOMARKERS; BIOPSY; CELLS, CULTURED; CHILD; DEXAMETHASONE; FEMALE; FIBROSIS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; PHENOTYPE; RECEPTORS, CELL SURFACE; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84939244874     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-014-3023-0     Document Type: Article

References (24)

1. Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, Croker BP, Droz D, Dunnill MS, Halloran PF (1993) International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 44:411–422
2. Shrestha BM, Haylor J (2014) Biological pathways and potential targets for prevention and therapy of chronic allograft nephropathy. Biomed Res Int 2014:482438
3. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madriga L, Salomon DR, Seron D, Sheaff M, Weening JJ (2007) Banff ‘05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’). Am J Transplant 7:518–526
4. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M (2008) Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 8:753–760
5. Croker BP, Clapp WL, Abu Shamat AR, Kone BC, Peterson JC (1996) Macrophages and chronic renal allograft nephropathy. Kidney Int Suppl 57:S42–S49
6. Liu G, Yang H (2013) Modulation of macrophage activation and programming in immunity. J Cell Physiol 228:502–512
7. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M (2013) Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 229:176–186
8. Anders HJ, Ryu M (2011) Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 80:915–925
9. Mannon RB (2012) Macrophages: contributors to allograft dysfunction, repair, or innocent bystanders? Curr Opin Organ Transplant 17:20–25
10. Ikezumi Y, Suzuki T, Karasawa T, Hasegawa H, Yamada T, Imai N, Narita I, Kawachi H, Polkinghorne KR, Nikolic-Paterson DJ, Uchiyama M (2011) Identification of alternatively activated macrophages in new-onset paediatric and adult immunoglobulin A nephropathy: potential role in mesangial matrix expansion. Histopathology 58:198–210
11. Ikezumi Y, Suzuki T, Karasawa T, Hasegawa H, Kawachi H, Nikolic-Paterson DJ, Uchiyama M (2010) Contrasting effects of steroids and mizoribine on macrophage activation and glomerular lesions in rat thy-1 mesangial proliferative glomerulonephritis. Am J Nephrol 31:273–282
12. Lan HY, Mu W, Nikolic-Paterson DJ, Atkins RC (1995) A novel, simple, reliable and sensitive method for multiple immunoenzymic staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem 43:97–102
13. Han Y, Ma FY, Tesch GH, Manthey CL, Nikolic-Paterson DJ (2013) Role of macrophages in the fibrotic phase of rat crescentic glomerulonephritis. Am J Physiol Renal Physiol 304:F1043–1053
14. Tse GH, Hughes J (2013) Macrophages and transplant rejection: a novel future target. Transplantation 96:946–948
15. Kanlaya R, Sintiprungrat K, Thongboonkerd V (2013) Secreted products of macrophages exposed to calcium oxalate crystals induce epithelial mesenchymal transition of renal tubular cells via RhoA-dependent TGF-β1 pathway. Cell Biochem Biophys 67:1207–1215
16. Tan TK, Zheng G, Hsu TT, Lee SR, Zhang J, Zhao Y, Tian X, Wang Y, Wang YM, Cao Q, Wang Y, Lee VW, Wang C, Zheng D, Alexander SI, Thompson E, Harris DC (2013) Matrix metalloproteinase-9 of tubular and macrophage origin contributes to the pathogenesis of renal fibrosis via macrophage recruitment through osteopontin cleavage. Lab Invest 93:434–449
17. Ko GJ, Boo CS, Jo SK, Cho WY, Kim HK (2008) Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. Nephrol Dial Transplant 23:842–852
18. Alidousty C, Rauen T, Hanssen L, Wang Q, Alampour-Rajabi S, Mertens PR, Bernhagen J, Floege J, Ostendorf T, Raffetseder U (2014) Calcineurin-mediated YB-1 dephosphorylation regulates CCL5 expression during monocyte differentiation. J Biol Chem 289:21401–21412
19. Höcker B, Tönshoff B (2009) Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview. Paediatr Drugs 11:381–396
20. Yang H (2006) Maintenance immunosuppression regimens: conversion, minimization, withdrawal, and avoidance. Am J Kidney Dis 47:S37–51
21. Ishikawa H (1999) Mizoribine and mycophenolate mofetil. Curr Med Chem 6:575–597
22. Ju MK, Huh KH, Park KT, Kim SJ, Cho BH, Kim CD, So BJ, Kang CM, Lee S, Joo DJ, Kim YS (2013) Mizoribine versus mycophenolate mofetil in combination therapy with tacrolimus for de novo kidney transplantation: evaluation of efficacy and safety. Transplant Proc 45:1481–1486
23. Helal I, Chan L (2011) Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation. Transplant Proc 43:472–477
24. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK (2001) Identification of the haemoglobin scavenger receptor. Nature 409(6817):198–201